Results 61 to 70 of about 6,506,258 (188)
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley +1 more source
Mantle cell lymphoma has features of both indolent and aggressive non-Hodgkin lymphomas. Repeated relapses leading to treatment failure in patients with mantle cell lymphoma might suggest the presence of cancer stem cells.
이승태
core +1 more source
Abstract CD19‐directed CAR‐T cell therapy has become the standard of care for the treatment of relapsed/refractory LBCL, MCL, FL and BCP‐ALL. Expansion of CAR‐T cells in the peripheral blood (PB) of patients in the first weeks after infusion is an important biomarker for the prediction of therapy response and occurrence of toxicities.
Gerulf Hänel +16 more
wiley +1 more source
Blastoid Variant Mantle Cell Lymphoma with Amplified IGH/CCND1 Fusion: A Unique Case and Current Literature Review [PDF]
Mantle cell lymphoma (MCL) is a subtype of mature B-cell non-Hodgkin lymphoma (NHL). Most cases exhibit CCDN1/IGH translocation; however, reports indicate that amplification of the fusion gene is extremely rare.
Haci Hasan Esen +3 more
core +1 more source
Abstract Prime editing, a novel clustered regularly interspaced short palindromic repeats (CRISPR)‐based technology, fuses a reverse transcriptase (RT) to an engineered CRISPR‐associated protein 9 (Cas9) and uses a prime editing guide RNA (pegRNA)‐encoded template.
Tianshan Ji +4 more
wiley +1 more source
Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop [PDF]
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma typically characterized by cyclin D1 overexpression as result of the t(11;14) translocation. MCL is biologically and clinically heterogeneous and frequently involves extranodal dissemination.
Michael E, Williams +7 more
openaire +2 more sources
Bortezomib‐based chemotherapy achieved an 88.9% remission rate in Chinese pediatric patients with relapsed/refractory B‐cell acute lymphoblastic leukemia, enabling 62.5% of responders to bridge to transplantation, while T‐cell acute lymphoblastic leukemia showed no response.
Xingyu Zhao +5 more
wiley +1 more source
Abstract Topic This systematic review and meta‐analysis evaluated the association between retinal vein occlusion (RVO) and lymphoma across two complementary evidence components: a qualitative clinical synthesis of RVO occurring in patients with lymphoma and a quantitative synthesis of subsequent cancer outcomes in patients with RVO. For the qualitative
Kai‐Yang Chen +2 more
wiley +1 more source
Mantle cell lymphoma is a relatively rare type of mature B-cell non-Hodgkin’s lymphoma with an incidence of approximately 8 cases per million persons per year.
Jared Williams, Shingi Chiruka
doaj +1 more source
High versus low baseline CAR‐HEMATOTOX scores were associated with poorer safety and efficacy outcomes in patients with R/R B‐NHL who received odronextamab in the ELM‐1 and ELM‐2 studies. The CAR‐HEMATOTOX score may provide a readily available measure for identifying patients at risk of inferior clinical outcomes with odronextamab treatment.
Matthew Matasar +9 more
wiley +1 more source

